<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663518</url>
  </required_header>
  <id_info>
    <org_study_id>TTI-621-01</org_study_id>
    <nct_id>NCT02663518</nct_id>
  </id_info>
  <brief_title>A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trillium Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trillium Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory
      hematologic malignancies and selected solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies
      and selected solid tumors.

      TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the
      sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of
      human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from
      delivering an inhibitory &quot;do not eat&quot; (anti phagocytic) signal to macrophages.

      This trial will be conducted in 2 phases and 4 parts: Phase 1a Part 1 (escalation phase) and
      Phase 1b Parts 2-4 (expansion phase).

      In the dose Escalation Phase (phase 1a Part 1), subjects with lymphoma will be enrolled in
      sequential dose cohorts to receive TTI-621 to characterize safety, tolerability,
      pharmacokinetics, and the maximum-tolerated dose (MTD).

      In the Expansion Phase (phase 1b Parts 2-4), TTI-621 will be given to subjects with a variety
      of hematologic malignancies and selected solid tumors to further define safety and to
      characterize efficacy. In the Expansion Phase Part 2, the safety and efficacy of TTI-621 will
      also be assessed when it is given in combination with other anti-cancer drugs. The dose of
      TTI-621 to be delivered in the Expansion Phase Parts 2-3 of the study may be increased or
      decreased based on the subject's tolerability and on the subject's response to treatment.

      In the phase 1b dose optimization of the study (Part 4), further dose escalation of TTI-621,
      beyond the dose determined during phase 1a dose escalation, will be pursued in patients with
      relapsed and/or refractory CTCL following a 3+3 escalation design and using a revised DLT
      criteria to further evaluate the safety and tolerability of TTI-621 at dose levels higher
      than the initially recommended phase 1b Parts 2-3.

      Secondary objectives include further characterization of the pharmacokinetics,
      pharmacodynamics, and development of ADA; and to gain preliminary evidence of the anti-tumor
      activity of TTI-621 in subjects with a variety of hematologic malignancies and selected solid
      tumors. In addition, the safety of TTI-621 will be evaluated in combination with other
      anti-cancer agents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>42 months</time_frame>
    <description>Safety and tolerability of TTI-621 when given alone and in combination with other anti-cancer agents to subjects with a variety of hematologic malignancies and with selected solid tumors, and to evaluate the safety of a standardized intra-subject TTI-621 dose intensification schedule.
Part 4: To further evaluate the safety and tolerability of TTI-621 at dose levels higher than the initially recommended phase 1b Parts 2 and 3 dose and to reassess the MTD and/or recommended phase 2 dose per revised DLT criteria following a 3+3 dose escalation schema.</description>
  </primary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TTI-621 Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Escalation Phase will include multiple doses of TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indolent B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hodgkin Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Lymphocytic Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Lymphoblastic Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Myeloid Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloproliferative Neoplasms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral T-Cell Lymphoma (PTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4: Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion Part 4 (Dose Optimization) cohort with TTI-621</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621</intervention_name>
    <description>Monotherapy</description>
    <arm_group_label>Acute Lymphoblastic Leukemia</arm_group_label>
    <arm_group_label>Acute Myeloid Leukemia</arm_group_label>
    <arm_group_label>Aggressive B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Chronic Lymphocytic Leukemia</arm_group_label>
    <arm_group_label>Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_label>Hodgkin Lymphoma</arm_group_label>
    <arm_group_label>Indolent B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <arm_group_label>Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>Myeloproliferative Neoplasms</arm_group_label>
    <arm_group_label>Part 4: Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_label>Peripheral T-Cell Lymphoma (PTCL)</arm_group_label>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>T-Cell Lymphoma</arm_group_label>
    <arm_group_label>TTI-621 Escalation Phase</arm_group_label>
    <other_name>SIRPαFc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 plus Rituximab</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Rituximab Combination</arm_group_label>
    <other_name>TTI-621 plus Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 plus Nivolumab</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Nivolumab Combination</arm_group_label>
    <other_name>TTI-621 plus Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced measurable malignancy

          2. Adequate hematologic status

          3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1
             prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will
             be considered a systemic therapy. Local radiation and topical agents are not systemic
             therapies.

          4. Adequate coagulation function

          5. Adequate hepatic function

          6. Adequate renal function

        Exclusion Criteria:

          1. Known, current central nervous system disease involvement or untreated brain
             metastases

          2. Allogeneic transplant within 30 days prior to the planned start of treatment or
             subjects with active graft-vs-host disease with the exception of Grade 1 skin
             involvement

          3. History of hemolytic anemia or bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathleen Roberge, NP-C, MSN, MSc</last_name>
    <phone>857-412-7029</phone>
    <phone_ext>211</phone_ext>
    <email>kathleen@trilliumtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaping Shou, MD, PhD</last_name>
    <email>yaping@trilliumtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Mei</last_name>
      <email>mamei@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Fong</last_name>
      <email>sophiafong@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lyons</last_name>
      <phone>904-953-6826</phone>
      <email>Lyons.Christopher@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyce Turba</last_name>
      <phone>813-745-1706</phone>
      <email>elyce.turba@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ansell</last_name>
      <phone>855-776-0015</phone>
      <email>ansell.stephen@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Yannotti</last_name>
      <phone>551-996-5168</phone>
      <email>Kara.Yannotti@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Mesidor</last_name>
      <phone>212-263-4403</phone>
      <email>Antoine.Mesidor@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia Univeristy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freddy J. Loffredo</last_name>
      <email>fl2156@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Horwitz</last_name>
      <email>horwitzs@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjali Advani</last_name>
      <email>ADVANIA@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Monette</last_name>
      <phone>503-494-9455</phone>
      <email>monette@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue McCann</last_name>
      <phone>412-864-3681</phone>
      <email>mccannsa@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madeleine Duvic, MD</last_name>
      <phone>713-404-2594</phone>
      <email>mduvic@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Madeleine Duvic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Villa</last_name>
      <phone>604-877-6000</phone>
      <email>dvilla@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Philip</last_name>
      <phone>416-581-7823</phone>
      <email>Lindsay.Philip@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clincancerres.aacrjournals.org/content/clincanres/early/2017/01/09/1078-0432.CCR-16-1700.full.pdf</url>
    <description>TTI-621: a novel innate immune checkpoint inhibitor</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-Cell</keyword>
  <keyword>CTCL</keyword>
  <keyword>PTCL</keyword>
  <keyword>ALL</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>TTI-621</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Cutaneous T-Cell Lymphoma</keyword>
  <keyword>Peripheral T-Cell Lymphoma</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>CD47</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

